Regulatory FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development FDAThe U.S.RegulatoryGene Therapy PlatformRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) FDA The U.S. RegulatoryGene Therapy PlatformRead full story Post navigation Previous: FDA renews criticism of trial sponsors over transparencyNext: Lilly investing billions to prepare for overseas oral GLP-1 launches Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
